Sunday, September 20, 2026

Moderna Stock Went Down By Over 3% On Friday, Will it Recover Next Week?

ViaNews Editorial Team

December 5, 2020

Moderna Stock Went Down By Over 3% On Friday, Will it Recover Next Week?
Shares of Moderna slid 3.01% to $152.52 on Friday, after two consecutive sessions in a row of gains. Moderna's last close was $157.26, 17.03% below its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1428.1% for the ongoing quarter and 12348.6% for the next. The company's growth estimates for the current quarter is a negative 48.6% and positive 528.6% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Top and Bottom Yearly Value

Moderna's stock is valued at $152.52 on Friday, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna's Moving Average

Moderna's worth is way above its 50-day moving average of $88.87 and way higher than its 200-day moving average of $73.28.

Previous days news about Moderna

Moderna falls after Merck sells stake in the vaccine maker. According to Bloomberg Quint on Wed Dec 2, "Moderna Inc. fell in premarket trading in New York after Merck & Co. said it sold its stake in the biotechnology company that's in the midst of developing a Covid-19 vaccine." Moderna expects to provide up to 125 mil covid-19 vaccine doses globally in q1. According to Business Insider on Fri Dec 4, "Moderna Inc. said Thursday that it expects to have between 100 million and 125 million doses of its potential COVID-19 vaccine available globally in the first quarter of 2021, with 85 million-100 million of those available in the U.S. And 15 million-25 million of those available outside of the U.S." Moderna to provide Israel health ministry with additional 4 million doses of its covid-19 vaccine candidate. According to MarketWatch on Fri Dec 4, "Moderna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273. The amendment brings the total number of doses secured by Israel to 6 million."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com